Clinical significance of autoantibody detection in membranous nephropathy
10.3760/cma.j.cn114452-20240401-00171
- VernacularTitle:膜性肾病相关自身抗体检测的临床意义
- Author:
Jia LI
1
;
Rong DENG
;
Qingshui HUANG
Author Information
1. 南昌大学第一附属医院检验科，南昌 330006
- Keywords:
Glomerulonephritis, Membranous;
Target antigen;
Autoantibodies;
Disease diagnosis;
Disease prediction
- From:
Chinese Journal of Laboratory Medicine
2024;47(9):993-998
- CountryChina
- Language:Chinese
-
Abstract:
Membranous nephropathy (MN) is an autoimmune disease in the kidney glomerulus and one of the leading causes of nephrotic syndrome. It can be characterized by the regular immune complexes deposited between the podocyte and the glomerular basement membrane, causing nephrotic syndrome in adults. Early diagnosis and treatment of MN are of great importance. MN can be divided into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy (SMN) according to its etiology. Anti-M-type phospholipase A2 receptor (PLA2R) antibodies, anti-platelet reaction-protein type 1 7A domain (THSD7A) antibodies have been used for MN diagnosis. Since THSD7A, many target antigens such as neural epidermal growth factor-like 1 protein (NELL1), semaphorin 3B (Sema3B), protocadherins7 (PCDH7), serine protease HTRA1 (HTRA1), exostosin 1/exostosin 2 (EXT1/EXT2), and neural cell adhesion molecule1 (NCAM1) have been identified as MN-related biomarkers. The newly identified antigens are of unique clinical values, especially for PLA2R and THSD7A negative MN diagnosis.
